



HELLENIC REPUBLIC
**National and Kapodistrian
University of Athens**
EST. 1837

**Mayo Clinic & National and Kapodistrian
University of Athens:
Hematology & Oncology Course**
Updates of ASCO & EHA on Oncology & Hematology

29th of June
until 1st of July
2023

Athens, Greece
Hotel Divani Caravel



Scientific Program

BINOCRIT[®]

epoetin alfa

ZARZIO[®]

filgrastim

BINOZAR3831 10/2022

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Ανοσήριτα
ΟΛΕΣ τις αναπάνωτες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Πριν τη συνταγογράφηση
συμβουλευθείτε την πλήρη Περίληψη των
Χαρακτηριστικών του κάθε Προϊόντος.

SANDOZ A Novartis
Division

KAK: Sandoz GmbH

Biochemiestrasse 10, A-6250 Kundl, Αυστρία

Στοιχεία επικοινωνίας στην Ελλάδα: Novartis (Hellas) A.E.B.E./Sandoz division

Φραγκοκκλησιάς 7B, 151 25 Μαρούσι, Αθήνα, Τηλ.: 210 2811712, Φαξ: 210 6857655

Προωθείται από την εταιρεία:



DEMO ABEE
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ

21^ο χλμ Εθν. Οδού Αθηνών-Λαμίας,

145 68 Κρουσέρι, Αττικής, Ελλάδα

T: +30 210 8161802, F: +30 210 8161587

EDITORIAL

Dear Colleagues,

*It is with great pleasure that we hereby welcome you to the upcoming Hematology & Oncology Course to be held by the **National and Kapodistrian University of Athens in collaboration with Mayo Clinic, USA**. The goal of the Course is to present the latest data announced during the recent American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress, which took place in the first two weeks of June 2023 in Chicago and Frankfurt respectively.*

Seventy-five esteemed professors from the National and Kapodistrian University of Athens and Mayo Clinic will be presenting the newest data pertaining to the diagnosis and treatment of solid tumors, hematologic neoplasms, as well as other hematologic diseases and disorders associated with blood coagulation.

It should be noted that this is the very first event of this kind to be held in Greece, not to mention one that boasts the presence of distinguished scientists from one of the most important foundations in the world, namely Mayo Clinic. This Course will allow the Greek scientists who were not able to attend the meetings mentioned above to gain valuable insight into the latest developments in Oncology and Hematology.

I wish you an enjoyable stay in Athens and a fruitful congress.


Yours faithfully,

Thanos Dimopoulos



*Rector of the National and
Kapodistrian University of Athens*

Panos Savvides



*Senior Associate Consultant,
Hematology and Oncology, Mayo Clinic*

SCIENTIFIC PROGRAM

Thursday June 29th, 2023

08:00-08:30 (LOCAL) **Welcome, Introductions and Overview**

12:00-12:30 (CST) **Meletios-Athanasios Dimopoulos (GR), Panos Savvides (US)**

08:30-10:00 (LOCAL) **Lymphoma**

12:30-14:00 (CST) *Moderators:* **Stephen Ansell (US), Theodoros Vassilakopoulos (GR)**

Update in the Management of DLBCL

Theodoros Vassilakopoulos (GR)

Management of Hodgkin Lymphoma

Gita Thanarajasingam (US)

Updates on T-cell Lymphoma

Marina Siakantari (GR)

Update on Treatment of Follicular Lymphoma

Allison Rosenthal (US)

How I Treat Mantle Cell Lymphoma

Javier Munoz (US)

10:00-10:30 (LOCAL) **COFFEE BREAK**

14:00-14:30 (CST)

10:30-11:15 (LOCAL) **CLL**

14:30-15:15 (CST) *Moderator:* **Panayiotis Panayiotidis (GR)**

Updates in the Treatment of Newly Diagnosed CLL

Maria Angelopoulou (GR)

Molecular Biomarkers in Chronic Lymphocytic Leukemia

Sameer Parikh (US)

11:15-12:00 (LOCAL) **Chronic Myeloid Disorders**

15:15-16:00 (CST) *Moderator:* **Michalis Voulgarelis (GR)**

Updates in the Treatment of Myelofibrosis

Stavroula Giannouli (GR)

Updates in the Treatment of Polycythemia Vera and Essential Thrombocythemia

Naseema Gangat (US)

12:00-13:00 (LOCAL) **LUNCH BREAK**

14:15-17:00 (CST)

SCIENTIFIC PROGRAM

Thursday June 29th, 2023

- 13:00-13:45 (LOCAL)** **Melanoma / Cancer Epi & Prevention**
17:00-17:45 (CST) *Moderators: Theodora Psaltopoulou (GR), Flora Zagouri (GR)*
Updates in the Prevention of Cancer
Theodora Psaltopoulou (GR)
Universal Screening for Inherited Cancers: What is the evidence?
Jewel Samadder (US)
Updates in the Treatment of Melanoma
Roxana Dronca (US)
- 13:45-14:30 (LOCAL)** **H&N**
17:45-18:30 (CST) *Moderators: Amanda Psyrris (GR), Panos Savvides (US)*
Update on Oropharyngeal HPV-Positive Squamous Cell Cancer of the H&N
Amanda Psyrris (GR)
Update on Cancers of the H&N
Panos Savvides (US)
- 14:30-15:00 (LOCAL)** **COFFEE BREAK**
18:30-19:00 (CST)
- 15:00-15:45 (LOCAL)** **GU Bladder / Kidney**
19:00-19:45 (CST) *Moderator: Dionysios Mitropoulos (GR)*
Updates in the Treatment of Urothelial Cancer
Aristotelis Bamias (GR)
Updates in the Treatment of Renal Cell Cancer
Petros Grivas (US)
- 15:45-16:30 (LOCAL)** **GU Prostate / Testicular**
19:45-20:30 (CST) *Moderators: Konstantinos Stravodimos (GR), Ioannis Varkarakis (GR)*
Updates in the Treatment of Testicular Cancer
Michalis Liontos (GR)
Updates in the Treatment of Prostate Cancer
Alan Bryce (US)
- 16:30-17:00 (LOCAL)** **COFFEE BREAK**
20:30-21:00 (CST)

SCIENTIFIC PROGRAM

Thursday June 29th, 2023

17:00-17:30 (LOCAL) SATELLITE LECTURE (SANOFI)

21:00-21:30 (CST) Chair: Georgia Kaiafa (GR)

The role of chromosome 1q in Multiple Myeloma

Maria Gavriatopoulou (GR)

17:30-18:00 (LOCAL) SATELLITE LECTURE (JANSSEN-CILAG)

21:30-22:00 (CST) Chair: Eirini Katodritou (GR)

Targeting optimal outcomes for patients with newly diagnosed multiple myeloma, today and in the future

Maria Gavriatopoulou (GR)

18:00-18:30 (LOCAL) SATELLITE LECTURE (TAKEDA)

22:00-22:30 (CST) Chair: Dimitrios Tryfonopoulos (GR)

Optimizing Outcomes in ALK+ NSCLC: from diagnosis to treatment

Theodoros Tegos (GR)

18:30-19:00 (LOCAL) SATELLITE LECTURE (INTEGRIS)

22:30-23:00 (CST) Chair: Meletios-Athanasios Dimopoulos (GR)

Optimizing Outcomes by Changing Mode of Action in Multiple Myeloma treatment Sequencing: The role of XPO1

Evangelos Terpos (GR)

19:30-21:30 (LOCAL) Welcome Reception

23:30-01:30 (CST)

SCIENTIFIC PROGRAM

Friday June 30th, 2023

08:00-08:30 (LOCAL) **Mayo Clinic: The past, the Present and the Future**
12:00-12:30 (CST) *Moderator:* **Panos Savvides (US)**
Rafael Fonseca (US), Stephen Ansell (US), Tanius Bekaii-Saab (US)

08:30-09:30 (LOCAL) **GI HPB**
12:30-13:30 (CST) *Moderators:* **Tanius Bekaii-Saab (US), Evangelos Felekouras (GR)**
Updates in the Treatment of Biliary Tract Cancer
Michalis Karamouzis (GR)
Updates in the Treatment of Liver Cancer
Ioannis Elefsiniotis (GR)
Updates in the Treatment of Pancreas Cancer
Robert McWilliams (US)
Updates in the Treatment of Gastroesophageal Cancers
Mohamed Bassam Sonbol (US)

09:30-10:00 (LOCAL) **GI Luminal**
13:30-14:00 (CST) *Moderators:* **Christina Wu (US), Dimitris Schizas (GR)**
Emerging Targets in the Treatment Metastatic Colorectal Cancer
Daniel Ahn (US)
Management of Oligometastatic Disease in Colorectal Cancer
Bassel El-Rayes (US)

10:00-10:30 (LOCAL) **COFFEE BREAK**
14:00-14:30 (CST)

10:30-11:15 (LOCAL) **NSCLC**
14:30-15:15 (CST) *Moderators:* **Panos Savvides (US), Nikoletta Rovina (GR)**
Update on Management on Local/Regional NSCLC
Vinicius Ernani (US)
Update on Management on Metastatic NSCLC - Immunotherapy
Konstantinos Syrigos (GR)
Update on Management on Metastatic NSCLC - Targeted therapies
Anastasios Dimou (US)

SCIENTIFIC PROGRAM

Friday June 30th, 2023

11:15-12:00 (LOCAL) SCLC, Mesothelioma

13:15-14:00 (CST) Moderator: Panos Savvides (US)

Update on Management on SCLC

Konstantinos Leventakos (US)

Update on Management on other Thoracic Cancers

Aaron Mansfield (US)

Update on Antibody-Drug Conjugates for Lung Cancer

Elias Kotteas (GR)

12:00-13:00 (LOCAL) LUNCH BREAK

16:00-17:00 (CST)

13:00-13:45 (LOCAL) Myeloma

17:00-17:45 (CST) Moderators: Meletios-Athanasios Dimopoulos (GR), Rafael Fonseca (US)

Management of Newly Diagnosed Myeloma

Evangelos Terpos (GR)

Updates in the Management of Monoclonal Gammopathies

Shaji Kumar (US)

13:45-14:30 (LOCAL) Other Plasma Cell Neoplasms

17:45-18:30 (CST) Moderators: Meletios-Athanasios Dimopoulos (GR), Rafael Fonseca (US)

Management of Waldenstrom's Macroglobulinemia

Maria Gavriatopoulou (GR)

Primary Amyloidosis (AL amyloidosis)

Julie Rosenthal (US)

14:30-15:00 (LOCAL) COFFEE BREAK

18:30-19:00 (CST)

15:00-15:45 (LOCAL) Anemias

19:00-19:45 (CST) Moderators: Ronald Go (US), Marie-Christine Kyrtonis (GR)

Updates in Hemoglobinopathies

Antonis Kattamis (GR)

Updates in Autoimmune Hemolytic Anemia

Ronald Go (US)

Updates in the Management of Anemia in MDS

Panagiotis Diamantopoulos (GR)

SCIENTIFIC PROGRAM

Friday June 30th, 2023

15:45-16:30 (LOCAL) Thrombosis/Bleeding disorders

19:45-20:30 (CST) Moderators: Marianna Politou (GR), Argyri Gialeraki (GR)

Updates on Platelet Transfusion

Serena Valsami (GR)

Updates in Thrombotic Disorders

Meera Sridharan (US)

16:30-17:00 (LOCAL) COFFEE BREAK

20:30-21:00 (CST)

17:00-17:30 (LOCAL) SATELLITE LECTURE (ASTRA ZENECA)

21:00-21:30 (CST) Chair: Elena Solomou (GR)

PNH: The Importance of sustained terminal complement inhibition

Ioannis Asimakopoulos (GR)

17:30-18:00 (LOCAL) SATELLITE LECTURE (ABBVIE)

21:30-22:00 (CST) Chair: Evangelos Terpos (GR)

The road to personalized treatment in Multiple Myeloma

Maria Gavriatopoulou (GR)

18:00-18:45 (LOCAL) SATELLITE SYMPOSIUM (GSK)

22:00-22:45 (CST) *Optimizing clinical benefit and immunization in patients with multiple myeloma*

Chair: Anastasia Pouli (GR)

Sequencing novel treatments towards maximum clinical benefit for every patient

Emmanouil Spanoudakis (GR)

New developments in the protection against herpes zoster through vaccination

Maria Gavriatopoulou (GR)

20:00-22:00 (LOCAL) GALA DINNER

00:00-02:00 (CST)

SCIENTIFIC PROGRAM

Saturday July 1st, 2023

08:00-08:30 (LOCAL) **Special Session National and Kapodistrian University of Athens**
12:00-12:30 (CST) **Meletios-Athanasios Dimopoulos (GR), Theodora Psaltopoulou (GR)**

08:30-09:15 (LOCAL) **Acute Leukemias**
12:30-13:15 (CST) **Moderator: Flora Kontopidou (GR)**

Update on Management of Acute Lymphoblastic Leukemia
Vasiliki Pappa (GR)
Updates in Acute Myeloid Leukemia
James Foran (US)

09:15-10:00 (LOCAL) **Cellular Therapies**
13:15-14:00 (CST) **Moderators: Yi Lin (US), Evangelos Terpos (GR)**

Update on CAR-T Therapies for Acute Leukemias
Panagiotis Tsirigotis (GR)
The Role of CAR-T Therapy in Patients with Lymphoid Malignancy
Mohamed Kharfan Dabaja (US)

10:00-10:30 (LOCAL) **COFFEE BREAK**
14:00-14:30 (CST)

10:30-11:15 (LOCAL) **Breast**
14:30-15:15 (CST) **Moderators: Christos Papadimitriou (GR), Roberto Leon Ferre (US)**

Updates in the Treatment of Triple Negative Breast Cancer
Roberto Leon Ferre (US)
Updates in the Treatment of Relapsed Breast Cancer
Flora Zagouri (GR)

11:15-12:00 (LOCAL) **GYN NeuroOncology**
15:15-16:00 (CST) **Moderators: George Zografos (GR), Marciej Mrugala (US)**

Updates in the Treatment of Ovarian Cancer
Christos Papadimitriou (GR)
Updates in Neuro-Oncology
Marciej Mrugala (US)
Updates in Geriatric Oncology
Joleen Hubbard (US)

12:00-12:30 (LOCAL) **End of meeting & discussion**
16:00-16:30 (CST)

FACULTY - SCIENTIFIC TITLES

Daniel Ahn	Associate Professor of Medicine, and Hematology/Oncology Consultant, Mayo Clinic
Maria Angelopoulou	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Stephen Ansell	Professor of Medicine, and Division Chair, Hematology, Mayo Clinic
Ioannis Asimakopoulos	Hematologist, Assistant Curator B ¹ , Hematology Clinic and Transplant Unit Bone Marrow, Hospital "LAIKO", Athens-Greece
Aristotelis Bamias	Professor of Therapeutics-Internal Medicine-Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Tanios Bekaii-Saab	Professor of Medicine, and Consultant, Medical Oncology, Mayo Clinic
Alan Bryce	Professor of Medicine, and Division Chair, Hematology and Medical Oncology, Mayo Clinic
Panagiotis Diamantopoulos	Consultant Hematologist, Hematology Unit, Laiko Hospital, Athens-Greece
Meletios-Athanasios Dimopoulos	Professor of Hematology and Oncology, Rector of the National and Kapodistrian University of Athens, Athens-Greece
Anastasios Dimou	Assistant Professor of Oncology, and Consultant, Medical Oncology, Mayo Clinic
Roxana Dronca	Professor of Oncology, and Division Chair, Hematology and Medical Oncology, Mayo Clinic
Ioannis Elefsiniotis	Professor Department of Nursing, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Bassel El-Rayes	Division Director for Hematology and Oncology, University of Alabama at Birmingham
Vinicius Ermani	Assistant Professor of Medicine, and Senior Associate Consultant, Medical Oncology, Mayo Clinic
Evangelos Felekouras	Professor of Surgery, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Roberto Leon Ferre	Assistant Professor of Oncology, and Consultant, Medical Oncology, Mayo Clinic
Rafael Fonseca	Professor of Medicine, and Consultant, Hematology, Mayo Clinic
James Foran	Professor of Medicine, and Consultant, Hematology, Mayo Clinic
Naseema Gangat	Professor of Medicine, Instructor in Oncology, and Consultant, Hematology, Mayo Clinic
Maria Gavriatopoulou	Associate Professor of Medical Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Argyri Gialeraki	Associate Professor of Biochemistry Hemostasis, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece

FACULTY - SCIENTIFIC TITLES

Stavroula Giannouli	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Ronald Go	Professor of Medicine, and Consultant, Hematology, Mayo Clinic
Petros Grivas	Professor, Division of Medical Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center, Clinical Director, Genitourinary Oncology, UW Medicine
Joleen Hubbard	Assistant Professor of Oncology, and Instructor in Medicine, and Consultant, Medical Oncology, Mayo Clinic
Georgia Kaiafa	Associate Professor of Haematology, 1st Medical Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki-Greece
Michalis Karamouzis	Professor of Biochemistry Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Eirini Katodritou	Consultant Hematologist, Director, Department of Hematology, Theagenio Cancer Hospital, Thessaloniki-Greece
Antonis Kattamis	Professor of Pediatric Hematology-Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Mohamed Kharfan Dabaja	Professor of Medicine, and Consultant, Hematology, Mayo Clinic
Flora Kontopidou	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Elias Kotteas	Associate Professor of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Shaji Kumar	Professor of Medicine, and Consultant, Hematology, Mayo Clinic
Marie-Christine Kyrtsonis	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Konstantinos Leventakos	Associate Professor of Oncology, and Consultant, Medical Oncology, Mayo Clinic
Yi Lin	Professor of Medicine, and Assistant Professor of Oncology, and Consultant, Hematology, Mayo Clinic
Michalis Liontos	Assistant Professor of Medical Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Aaron Mansfield	Professor of Oncology, and Consultant, Medical Oncology, Mayo Clinic
Robert McWilliams	Professor of Oncology, and Consultant, Medical Oncology, Mayo Clinic
Dionysios Mitropoulos	Professor of Urology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece

FACULTY - SCIENTIFIC TITLES

Marciej Mrugala	Professor of Neurology, and Professor of Medicine, and Consultant, Neurology, Mayo Clinic
Javier Munoz	Associate Professor of Medicine, and Senior Associate Consultant, Hematology and Oncology, Mayo Clinic
Panayiotis Panayiotidis	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Christos Papadimitriou	Professor of Medical Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Vasiliki Pappa	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Sameer Parikh	Associate Professor of Medicine, and Assistant Professor of Oncology, and Consultant, Hematology, Mayo Clinic
Marianna Politou	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Anastasia Pouli	Consultant Hematologist, Director, Department of Hematology, "ST. SAVVAS" Oncology Hospital, Athens-Greece
Theodora Psaltopoulou	Professor of Epidemiology & Preventive Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Amanda Psyrris	Professor of Medical Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Allison Rosenthal	Assistant Professor of Medicine, and Consultant, Hematology and Oncology, Mayo Clinic
Julie Rosenthal	Assistant Professor of Medicine, and Consultant, Cardiology, Mayo Clinic
Nikoletta Rovina	Associate Professor of Pulmonology-Intensive Care, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Jewel Samadder	Professor of Medicine, and Consultant, Gastroenterology and Hepatology, Mayo Clinic
Panos Savvides	Senior Associate Consultant, Hematology and Oncology, Mayo Clinic
Dimitris Schizas	Associate Professor of Surgery, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Marina Siakantari	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Elena Solomou	Associate Professor of Medical Hematology, University of Patras, School of Medicine, Patras-Greece

FACULTY - SCIENTIFIC TITLES

Mohamed-Bassam Sonbol	Assistant Professor of Medicine, and Consultant, Medical Oncology, Mayo Clinic
Emmanouil Spanoudakis	Associate Professor of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis-Greece
Meera Sridharan	Assistant Professor of Medicine, and Assistant Professor of Oncology, and Consultant, Hematology, Mayo Clinic
Konstantinos Stravodimos	Professor of Urology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Konstantinos Syrigos	Professor of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Theodoros Tegos	Medical Oncologist, Curator B', Hospital "EVANGELISMOS", Athens-Greece
Evangelos Terpos	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Gita Thanarajasingam	Associate Professor of Medicine, and Instructor in Oncology, and Consultant, Hematology, Mayo Clinic
Dimitrios Tryfonopoulos	Medical Oncologist, Director 2nd Pathological Oncology Department, Hospital "AGIOS SAVVAS", Athens-Greece
Panagiotis Tsirigotis	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Serena Valsami	Associate Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Ioannis Varkarakis	Professor of Urology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Theodoros Vassilakopoulos	Professor of Hematology, National and Kapodistrian, University of Athens, School of Medicine, Athens-Greece
Michalis Voulgarelis	Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
Christina Wu	Professor of Medicine, and Senior Associate Consultant, Medical Oncology, Mayo Clinic
Flora Zagouri	Professor of Medical Oncology, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece
George Zografos	Professor of Surgery, National and Kapodistrian University of Athens, School of Medicine, Athens-Greece

abbvie





ΜΕΙΩΣΤΕ ΤΗΝ ΕΠΙΒΑΡΥΝΣΗ ΤΩΝ ΑΣΘΕΝΩΝ ΣΑΣ ΑΠΟ ΤΙΣ ΜΕΤΑΓΓΙΣΕΙΣ

Reblozyl[®]

(luspatercept)

Ο ΠΡΩΤΟΣ ΚΑΙ ΜΟΝΑΔΙΚΟΣ ΠΑΡΑΓΟΝΤΑΣ ΩΡΙΜΑΝΣΗΣ ΤΩΝ ΕΡΥΘΡΩΝ ΑΙΜΟΣΦΑΙΡΙΩΝ¹⁻³

Βιβλιογραφία: 1. REBLOZYL[®] Περίληψη Χαρακτηριστικών του Προϊόντος, Σεπτέμβριος 2022 2. Cappellini M.D. et al A phase 3 trial of Luspatercept in Patients with Transfusion-Dependent β -Thalassemia; N Engl J Med 2020;382:1219-31. DOI: 10.1056/NEJMoa1910182 3. Fenaux P. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndrome; N Engl J Med 2020;382:140-51. DOI: 10.1056/NEJMoa1908892

 Bristol Myers Squibb[™]

Bristol-Myers Squibb A.E.
Αττικής 49-53 & Προποντίδος 2,
Τ.Κ. 152 35 Βριλήσσια, Αττική
ΤΘ 63883 - Βριλήσσια,
Τ.Κ. 152 03, Αττική
Τηλ. 210 6074300 & 210 6074400,
Φαξ 210 6074333
Αριθμός Γ.Ε.ΜΗ 7453601000

Blue Box: Με περιορισμένη ιατρική συνταγή. Μόνο για νοσοκομειακή χρήση από ιατρό με κατάλληλη ειδικευση και εμπειρία.

Αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών:
Ελλάδα: Εθνικός Οργανισμός Φαρμάκων, Μεσογείων 284 GR-15562
Χολαργός, Αθήνα
Τηλ: + 30 21 32040380/337, Φαξ: + 30 21 06549585,
Ιστότοπος: <http://www.eof.gr>
Κύπρος: Φαρμακευτικές Υπηρεσίες, Υπουργείο Υγείας CY-1475
Λευκωσία
Τηλ: +357 22608607, Φαξ: + 357 22608669,
Ιστότοπος: <http://www.moh.gov.cy/phs>

Λιανική Τιμή:
Ελλάδα: Reblozyl 25mg 1.433,79 €. Reblozyl 75mg 4.208,09 €
Κύπρος: Reblozyl 25mg 1.581,36 €. Reblozyl 75mg 4.560,83 €

Για περισσότερες πληροφορίες
μπορείτε να ανατρέξετε στην
Περίληψη Χαρακτηριστικών του Προϊόντος,
σκανάροντας το QR code.



Ημερομηνία Ανασάφησης Κειμένου:
09/2022

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**



PADCEV™

enfortumab vedotin

Injection for IV infusion 20 mg & 30 mg vials



▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει τον γρήγορο προσδιορισμό νέων πληροφοριών ασφαλείας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιεσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.



Astellas Pharmaceuticals A. E. B. E.
Αιγυλλιάου 6-8, 151 23 Μαρούσι, Αθήνα.
Τηλ. 210 8189 900, Fax: 216 8008 998
www.astellas.com/gr

Τοπικός Αντιπρόσωπος/ Διανομέας
προϊόντων Astellas στην Κύπρο:
Novagem Ltd, Τηλ: 00357 22483858

Για περαιτέρω πληροφορίες συμβουλευτείτε την ΠΧΠ που διατίθεται από την
Astellas Pharmaceuticals ΑΕΒΕ, κατόπιν αιτήσεως.

	Νοσοκομειακή Τιμή	Χονδρική Τιμή	Λισιακή Τιμή με ΦΠΑ
PADCEV ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΣΚΕΥΑΣΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ 20MG/ML 1 VIAL	569,77€	633,71€	718,75€
PADCEV ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΣΚΕΥΑΣΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ 30MG/ML 1 VIAL	854,65€	950,55€	1063,00€

ΠΕΡΙΟΡΙΣΜΕΝΗ ΙΑΤΡΙΚΗ ΣΥΝΤΑΓΗ: ΜΟΝΟ ΓΙΑ ΝΟΣΟΚΟΜΕΙΑΚΗ
ΧΡΗΣΗ ΑΠΟ ΓΙΑΤΡΟ ΜΕ ΚΑΤΑΛΛΗΛΗ ΕΙΔΙΚΕΥΣΗ ΚΑΙ ΕΜΠΕΙΡΙΑ.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»

XOSPATA™

gilteritinib 40mg tablets



Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε

ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

ΟΝΟΜΑΣΙΑ ΜΟΡΦΗ ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ	ΔΡΑΣΤΙΚΗ ΟΥΣΙΑ	ΕΧ-FACTORY/ΤΙΜΗ ΠΑΡΑΓΩΓΟΥ	ΧΟΝΔΡΙΚΗ ΤΙΜΗ	ΝΟΣΟΚΟΜΕΙΑΚΗ ΤΙΜΗ
XOSPATA F.C.TAB 40MG/TAB ΒΤx84 Σιακία σε blisters (OPA/αλουμινίου/PVC/αλουμινίου)	GILTERITINIB	15.594,00 €	15.827,91 €	14.231,08 €

▽ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιεσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 της ΠΧΠ για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

Περιορισμένη Ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

Περαιτέρω πληροφορίες διατίθενται από τον κάτοχο της άδειας κυκλοφορίας κατόπιν αιτήσεως και περιλαμβάνονται στη συνοπτική περιγραφή χαρακτηριστικών του προϊόντος και το φύλλο οδηγιών χρήσης του φαρμάκου.

XOS/ADV3/04.2023 MAT-GR-XOS-2023-00009

 **astellas**

Astellas Pharmaceuticals A. E. B. E.
Αγνησιλάου 6-8, 151 23 Μαρούσι, Αθήνα
Τηλ. 210 8189 900, Fax: 216 8008 998

www.astellas.com/gr

Τοπικός Αντιπρόσωπος/
Διανομέας προϊόντων Astellas στην Κύπρο:
Novagem Ltd, Τηλ: 00357 22483858

Lenalidomide Accord

Σκληρά καψάκια

5mg

10mg

15mg

20mg

25mg



Ενδεικτική Λισαδική Τιμή:

Lenalidomide Accord 5mg	2.452,25 €
Lenalidomide Accord 10mg	2.402,76 €
Lenalidomide Accord 15mg	2.526,86 €
Lenalidomide Accord 20mg	3.183,03 €
Lenalidomide Accord 25mg	2.953,23 €

Lenalidomide Accord Τρόπος Διάθεσης:

Περιορισμένη Ιατρική Συνταγή. Η έναρξη της θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται εκτός νοσοκομείου υπό την παρακολούθηση ειδικού ιατρού.

Πριν τη συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος και το Εκπαιδευτικό Υλικό για τους Επαγγελματίες Υγείας.

W **WinMedica**
Serving Health for Life

Για περισσότερες πληροφορίες:

WIN MEDICA ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.

Οιδίποδος 1-3 & Παράδρομος Αττικής Οδού 33-35, 15238 Χαλάνδρι

Τηλ.: 2107488821, Fax: 2107488827

info@winmedica.gr, www.winmedica.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε **ΟΛΕΣ** τις ανεπιθύμητες ενέργειες για **ΟΛΑ** τα φάρμακα Συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»

Κάτοχος Άδειας Κυκλοφορίας: Accord Healthcare S.L.U.

accord
The Evolution of Generics

Global Generics & Biosimilars AWARDS 2018
COMPANY OF THE YEAR

Revlimid®
(lenalidomide)

Imnovid®
(pomalidomide)



Στο υποτροπιάζον και ανθεκτικό πολλαπλούν μυέλωμα (RRMM): ΣΥΝΕΧΙΣΤΕ ΜΕ IMiD® ΩΣ ΘΕΜΕΛΙΟ ΘΕΡΑΠΕΙΑΣ ΓΙΑ ΠΑΡΑΤΑΣΗ ΤΗΣ ΕΠΙΒΙΩΣΗΣ¹⁻⁶

 **Bristol Myers Squibb™**

Bristol-Myers Squibb A.E.
Αττικής 49-53 & Προποντίδος 2,
Τ.Κ. 152 35 Βριλησσία, Αττική
Τ.Θ. 63883 - Βριλησσία,
Τ.Κ. 152 03, Αττική
Τηλ. 210 6074300 & 210 6074400
Φαξ 210 6074333
Αριθμός Γ.Ε.ΜΗ 7453601000

BLUE BOX: Περιορισμένη ιατρική συνταγή. Η έναρξη της θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται εκτός νοσοκομείου υπό την παρακολούθηση ειδικού ιατρού.

Συνομογραφίες: RRMM (Relapsed Refractory Multiple Myeloma): Υποτροπιάζον Ανθεκτικό Πολλαπλούν Μυέλωμα

Βιβλιογραφία:

1. Siegel DS, et al. Br J Haematol. 2020;188:501-510. 2. San Miguel JF, et al. Haematologica. 2015;100(10):1334-1339. 3. San Miguel J, et al. Lancet Oncol. 2013;14(11):1055-1066. 4. Dimopoulos MA, et al. Haematologica. 2015;100(10):1327-1333. 5. Moreau P, et al. Leuk. Lymphoma. 2016;57(12):2839-2847. 6. Paludo J, et al. Blood. 2017;130(10):1198-1204.

Λιανική Τιμή IMNOVID®:	Ελλάδα	Κύπρος
IMNOVID CAPS 1MG/CAP BΤx21 (PVC/PCTFE Blister)	7.597,09€	8.004,19€
IMNOVID CAPS 2MG/CAP BΤx21 (PVC/PCTFE Blister)	7.814,71€	8.167,71€
IMNOVID CAPS 3MG/CAP BΤx21 (PVC/PCTFE Blister)	8.056,12€	8.353,17€
IMNOVID CAPS 4MG/CAP BΤx21 (PVC/PCTFE Blister)	7.804,20€	8.484,09€

Λιανική Τιμή REVIMID®:	Ελλάδα	Κύπρος
REVIMID CAPS 5 MG/CAP Χάρτινη συσκευασία x 21 (σε BLISTERS PCTFE/PVC/ALU)	3.482,99€	4.337,71€
REVIMID CAPS 10 MG/CAP Χάρτινη συσκευασία x 21 (σε BLISTERS PCTFE/PVC/ALU)	3.404,41€	4.522,48€
REVIMID CAPS 15 MG/CAP Χάρτινη συσκευασία x 21 (σε BLISTERS PCTFE/PVC/ALU)	3.588,97€	4.684,01€
REVIMID CAPS 20MG/CAP BΤ x21 (BLIST 3x7) (σε BLISTERS PVC/PCTFE/ελαστικό)	4.543,05€	
REVIMID CAPS 25 MG/CAP Χάρτινη συσκευασία x 21 (σε BLISTERS PCTFE/PVC/ALU)	4.204,79€	4.999,82€

Για περισσότερες πληροφορίες σχετικά με το IMNOVID® μπορείτε να ανατρέξετε στην Περίληψη Χαρακτηριστικών του Προϊόντος, ανακτώντας το QR code.



Ημερομηνία Αναθεώρησης Κειμένου: 9/12/2021

Για περισσότερες πληροφορίες σχετικά με το REVIMID® μπορείτε να ανατρέξετε στην Περίληψη Χαρακτηριστικών του Προϊόντος, ανακτώντας το QR code.



Ημερομηνία Αναθεώρησης Κειμένου: 14/10/2022

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφάρτε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «KITPINH ΚΑΡΤΑ»